GET DAILY SIGNALSCVRx (CVRX) Analyst Mean Target at $2.25 Points to +159% Upside After Recent Sell-Off
Key Takeaways
- The central target of $2.25 is the arithmetic mean of five recent analyst price targets reviewed, ranging from $1.25 to $5.00 — not a single firm's forecast or an official published consensus.
- The stock trades near $0.87 after a sharp single-session decline following a third-quarter revenue miss and a cut to full-year guidance.
- Reaching $2.25 would require a rise of roughly 159% — a very large move from current levels.
- Supportive factors include 87% gross margins, roughly $58.7 million in cash (about 18 months of runway), and new Medicare Advantage coverage policies.
- The biggest risks are deteriorating reimbursement, physician-champion turnover, and weak field execution.
- For more on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
- Discover automated trading ideas with Trending AI Robots.
Analyst Price Targets and Consensus View
CVRx, Inc. (CVRX) is a Minneapolis-based, commercial-stage medical device company whose flagship product, Barostim, delivers baroreflex activation therapy for heart failure. Following its third-quarter report, analysts sharply reduced their price targets. The five most recent targets reviewed are Craig-Hallum at $1.25 (Hold), Piper Sandler at $1.50 (Neutral), Lake Street at $1.50 (Hold), Canaccord Genuity at $2.00 (Hold, downgraded from Buy), and Cantor Fitzgerald at $5.00 (Overweight).
The arithmetic mean of these five targets is $2.25, with a wide range of $1.25 to $5.00. Four targets were set on November 6, 2026, in the immediate aftermath of earnings; Cantor Fitzgerald's $5.00 was last revised in August 2026 and had not been updated following the latest guidance cut, which helps explain the unusually wide spread. In my view, this dispersion highlights how quickly sentiment shifted.
Views are cautious rather than bullish. Canaccord's downgrade cited headwinds "increasingly outside its control" with "no clear timeline for relief." Piper Sandler pointed to misses on domestic units placed and active implanting centers. Cantor's Overweight rating stands as the notable exception, reflecting a more constructive long-term view of Barostim adoption. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The latest verified price is approximately $0.87 as of the November 6, 2026 close, after a decline of roughly 41% in a single session. Reaching the $2.25 central target implies upside of about 159%, which qualifies as a very large move. The shares now trade far below their 200-day moving average and near multi-year lows.
The company reported third-quarter revenue of $13.8 million, down 6.1% year over year and below estimates, with a GAAP EPS loss of $0.52. Management lowered full-year 2026 revenue guidance to $56–57 million from $58–60 million and guided fourth-quarter revenue to $11.7–12.7 million, indicating the reset may not be complete. Reaching $2.25 would require a meaningful reversal of revenue momentum and a return of investor confidence in the commercial strategy.
What Could Support a Move Toward the Target
Several factors could underpin a recovery. Gross margin held steady at 87%, and the company ended September with about $58.7 million in cash, which management estimates provides at least 18 months of runway. CVRx has secured two written Medicare Advantage coverage policies, including one from Humana, representing roughly 21% of Medicare Advantage covered lives. Enrollment in the BENEFIT-HF trial is running ahead of plan, and effective October 1 the national average inpatient payment rate rose to about $45,000.
Management also noted that sales-force turnover fell to its lowest level in more than two years, and five of nine U.S. regions were growing procedures by more than 20% on average — evidence that execution is stabilizing in more tenured territories. From what I see, these operational details matter more than the headline numbers right now.
What Could Prevent the Target From Being Reached
The principal obstacle is reimbursement. The company's largest Medicare Advantage payer has slowed approvals dramatically: the 30-day approval rate fell to about 12% from a high of 83% in 2025, and the overall Medicare Advantage approval rate dropped to 51% from 60% in the second quarter. Some hospitals are pausing implants while they confirm payment across their payer mix, and at least one large health system has held more than a dozen approved patients for multiple quarters.
Physician-champion turnover and uneven field execution continue to weigh on implant growth, and U.S. revenue fell 4% while European revenue dropped 27% in the quarter. With no clear timeline for reimbursement relief and ongoing losses, valuation support remains limited. I’m watching this closely because reimbursement trends often determine whether recovery stories play out.
Technical Levels and Market Structure
The stock's sharp breakdown has left it trading near multi-year lows, well below its longer-term moving averages, which had been around $5 before the decline. The $1.00 round-number level and the lowest current analyst target of $1.25 now sit as nearby overhead reference points. A durable recovery would likely need to reclaim these levels before the broader $2.25 target comes into view.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though specific horizons vary by firm. Investors should watch the next quarterly report for evidence that the weaker regions have stopped shrinking, that the largest payer's approval rates have stabilized, and that 2027 guidance shows a credible return to growth. Reimbursement developments, prior-authorization approval trends, analyst revisions, and cash-burn updates are all material to the target.
Exploring AI-Driven Signals
I’ve found Tickeron’s AI Daily Buy/Sell Signals useful for keeping an objective eye on names like this one. The tool continuously monitors thousands of stocks and ETFs to generate Buy, Sell, or Hold signals based on technical behavior and market conditions, which can help complement fundamental work when volatility is high.
Final Assessment
The $2.25 central target is the mean of five recent analyst targets across a wide $1.25–$5.00 range, and it would require a very large move of roughly 159% from the current price near $0.87. The bull case rests on high gross margins, a solid cash position, improving coverage, and early signs of sales-force stabilization. The bear case centers on persistent reimbursement delays, guidance cuts, and no clear timeline for relief. Given the disagreement among analysts and the magnitude of the reset, the path to $2.25 depends first on evidence that revenue has bottomed and that payer behavior is improving — conditions that remain unproven.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CVRX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CVRX turned positive on October 20, 2026. Looking at past instances where CVRX's MACD turned positive, the stock continued to rise in 41 of 46 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CVRX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +15.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVRX advanced for three days, in 245 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
CVRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 57 cases where CVRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVRX as a result. In 67 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CVRX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.160) is normal, around the industry mean (4.142). P/E Ratio (-0.441) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.292) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. CVRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement